Abstract
Endothelial cells (EC) produce platelet activating factor (PAF) and prostacyclin (PGI2) in response to inflammatory agents such as thrombin. Upon cell stimulation a calcium-dependent phospholipase A2 (PLA2) is activated which hydrolyzes a membrane phospholipid to yield 1-0-alkyl-2-lyso-sn-glycero-3-phospho-choline (lyso-PAF) and free arachidonic acid. Lyso-PAF is in turn converted into PAF by a specific acetyltransferase and arachidonic acid is metabolized via cyclic endoperoxides to PGI2. In the present study we report that S35b (4-methyl-3-phenylsulfonylfuroxan), an new phenyl-sulfonylfuroxan compound with potent antiaggregatory effect, inhibits thrombin-induced PAF synthesis and acetyltransferase activation as well as PGI2 production in human umbilical vein endothelial cells (HUVEC) in a concentration dependent way. Additionally, we show that S35b stimulates the production of cyclic GMP (cGMP) in HUVEC in a concentration- and time-dependent manner. At high concentration, S35b potentiates the cAMP increase induced by iloprost or forskolin without having a significant influence on cAMP level itself. Potentiation of cAMP increase during agonist-induced EC stimulation seems not to be important for the effect of S35b on cellular function as the compound is active in inhibiting PAF production when endothelial cells are pretreated with indomethacin to block PGI2 synthesis. The increase of cGMP evoked by S35b may account for the effect on endothelial cell function.
Similar content being viewed by others
References
G. Camussi, M. Aglietta, F. Malavasi, C. Tetta, W. Piacibello, F. Sanavio and F. Bussolino,The release of platelet-activating factor from human endothelial cells in culture. J. Immunol.131, 2397–2403 (1983).
S. M. Prescott, G. A. Zimmerman and T. M. McIntyre,Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glyceryl-3-phosphocholine) when stimulated with thrombin. Proc. Natl. Acad. Sci. USA81, 3934–3938 (1984).
T. M. McIntyre, G. A. Zimmerman, K. Satoh and S. M. Prescott,Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykimin and adenosine triphosphate. J. Clin. Invest.76, 271–280 (1985).
E. A. Jaffe, J. Grulich, B. B. Weksler, G. Hampel and K. Watanabe,Correlation between thrombin-induced prostacyclin production and inositol trisphosphate and cytosolic free calcium levels in cultured human endothelial cells. J. Biol. Chem.262, 9557–8565 (1987).
T. J. Hallam, J. D. Pearson and L. A. Needham,Thrombin-stimulated elevation of human endothelial-cell cytoplasmic free calcium concentration causes prostacyclin production. Biochem. J.251, 243–249 (1988).
P. Braquet, T. Y. Shen, L. Touqui and B. B. Vargaftig,Perspectives in platelet-activating factor research. Pharmacol. Rev.39, 97–145 (1987).
S. M. Prescott, G. A. Zimmerman and T. M. McIntyre,Plateletactivating factor. J. Biol. Chem.265, 17381–17384 (1990).
F. Snyder,Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am. J. Physiol.259, C697-C708 (1990).
G. A. Zimmerman, T. M. McIntyre, M. Mehra and S. M. Prescott,Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. J. Cell Biol.110, 529–540 (1990).
R. Gryglewski, S. Bunting, S. Moncada, R. Flower and J. R. Vane,Mediators produced by the endothelial cell. Hypertension12, 530–548 (1988).
J. R. Vane,Regulatory function of the vascular endothelium. N. Engl. J. Med.323, 27–36 (1990).
S. M. Prescott, T. M. McIntyre and G. A. Zimmerman,The role of platelet-activating factor in endothelial cells. Thromb. Haemostas.64, 99–103 (1990).
M. Hirafuji, J. M. Mencia-huerta and J. Benveniste,Regulation of PAF-acether (platelet-activating factor) biosynthesis in cultured human vascular endothelial cells stimulated with thrombin. Biochim. Biophys. Acta,930, 359–369 (1987).
D. Ghigo, F. Bussolino, G. Garbarino, R. Heller, F. Turrini, G. P. Pescarmona, E. J. Cragoe Jr., L. Pegoraro and A. Bosia,Role of Na +/H + exchange in thrombin-induced platelet-activating factor production by human endothelial cells. J. Biol. Chem.263, 19437–19446 (1988).
R. E. Whatley, P. Nelson, G. A. Zimmerman, D. L.Stevens, C. J. Parker, T. M. McIntyre and S. M. Prescott,The regulation of platelet-activating factor production in endothelial cells: the role of calcium and protein kinase. C. J. Biol. Chem.264, 6325–6333 (1989).
G. B. Zavoico, J. K. Hrbolich, M. A. Gimbrone and A. I. Schafer,Enhancement of thrombin- and ionomycin-stimulated prostacyclin and platelet-activating factor production in cultured endothelial cells by a tumor-promoting phorbol ester. J. Cell. Physiol.143, 596–605 (1990).
R. Heller, F. Bussolino, D. Ghigo, G. Garbarino, H. Schröder, G. Pescarmona and A. Bosia,Protein kinase C and cyclic AMP modulate thrombin-induced platelet-activating factor synthesis in human endothelial cells. Biochim. Biophys. Acta1093 55–64 (1991).
F. H. Chilton and T. R. Connell,1-Ether-linked phosphoglycerides, Major endogenous sources of arachidonate in the human neutrophil. J. Biol. Chem.263, 5260–5265 (1988).
R. E. Whatley, G. A. Zimmerman, T. M. McIntyre, R. Taylor and S. M. Prescott:Production of platelet-activating factor by endothelial cells. Semin. Thromb. Hemostas. 13, 445–453 (1987).
B. B. Weksler, A. J. Markus and E. A. Jaffe,Synthesis of prostaglandin I 2 (prostacyclin) by cultured human and bovine endothelial cells. Proc. Natl. Acad. Sci. USA74, 3922–3926 (1977).
A. I. Schafer, D. D. Crawford and M. A. Gimbrone,Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells. J. Clin. Invest.73, 1105–1108 (1984).
M. G. Lampugnani, M. Pedenovi, E. Dejana, D. Rotilio, M. B. Donati, F. Bussolino, G. Garbarino, D. Ghigo and A. Bosia,Human α-thrombin induces phosphoinositide turnover and Ca ++ movements in cultured human umbilical vein endothelial cells. Thromb. Res.54, 75–87 (1989).
M. J. Berridge,Inositol trisphosphate and diacylglycerol, two interacting second messengers. Annu. Rev. Biochem.56, 159–193 (1987).
R. Heller, F., Bussolino, D. Ghigo, G. Garbarino, G. P. Pescarmona, U. Till and A. Bosia,Nitrovasodilators inhibit thrombin-induced platelet-activating factor synthesis in human endothelial cells. Biochem. Pharmacol.44, 223–229 (1992).
D. Ghigo, R. Heller, R. Calvino, P. Alessio, R. Fruttero, A. Gasco, A. Bosia and G. Pescarmona,Characterization of a new compound, S35b, as a guanylate cyclase activator in human platelets. Biochem. Pharmacol.43, 1281–1288 (1992).
A. L. Steiner, C. W. Parker and D. M. Kipnis,Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J. Biol. Chem.247, 1106–1113 (1972).
E. G. Bligh and W. J. Dyer,A rapid method of total lipid extraction and purificaton. Can. J. Biochem. Physiol.37, 911–917 (1959).
G. A. Zimmerman, R. E. Whatley, T. M. McIntyre, D. M. Benson and S. M. Prescott,Endothelial cells for studies of plateletactivating factor and arachidonate metabolites. In Methods in Enzymology, Vol.187, (Ed R. C. Murphy and F. A. Fitzpatrick) pp. 520–535. Academic Press Inc. 1990.
F. Bussolino, F. Gremo, C. Tetta, G. P. Pescarmona and G. Camussi,Production of platelet-activating factor by chick retina. J. Biol. Chem.261, 16502–16508 (1986).
F. Snyder, M. Blank, T.-C. Lee, M. Robinson and D. Woodard,Measurements of key enzyme activities involved in the metabolism of platelet activating factor. In Methods in Enzymology, Vol.141, (Ed. R. C. Murphy and F. A. Fitzpatrick) pp. 379–396, Academic Press Inc. 1987.
A. M. Marcus, B. B. Weksler, E. A. Jaffe and M. J. Broekman,Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J. Clin. Invest.66, 979–986 (1980).
R. Calvino, R. Fruttero, D. Ghigo, A. Bosia, G. P. Pescarmona and A. Gasco,4-Methyl-3-(R-sulfonyl)-furoxans: a new class of potent inhibitors of the platelet aggregation. J. Med. Chem.35, 3296–3300 (1992).
C. Lugnier, P. Schoeffter, A. Le Bec, E. Strouthou and J. C. Stoclet,Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol.35, 1743–1751 (1986).
E. Noack and M. Feelisch,Molecular aspects underlying the vasodilator action of molsidomine. J. Cardiovasc. Pharmacol.14 (Suppl. 11) S1-S5 (1989).
M. Feelisch and E. Noack,Nitric oxide (NO) formation from nitrovasodilators occurs independently of hemoglobin or nonheme iron. Eur. J. Pharmacol.142, 465–469 (1987).
M. Feelisch, J. Ostrowski and E. Noack,On the mechanism of NO release from sydnonimines. J. Cardiovasc. Pharmacol.14 (Suppl. 11, S13-S22 (1989).
S. A. Waldman and F. Murad,Cyclic GMP synthesis and function. Pharmacol. Rev.39, 163–196 (1987).
S. Nakashima, T. Tohmatsu, H. Hattori, Y. Okano and Y. Nozawa,Inhibitory action of cyclic GMP on secretion, polyphosphoinositide hydrolysis and calcium mobilization in thrombinstimulated human platelets. Biochem. Biophys. Res. Commun.135, 1099–1104 (1986).
M.-F. Simon, H. Chap and L. Douste-Blazy,Effect of a stimulant of guanylate cyclase, SIN-1, on calcium movements and phospholipase C activation in thrombin-stimulated human platelets. Biochem. Pharmacol.37, 1263–1269 (1988).
M. Hirata, K. P. Kohse, C.-H. Chang, T. Ikebe and F. Murad,Mechanism of cyclic GMP inhibition of inositol phosphate formation in rat aorta segments and cultured bovine aortic smooth muscle cells. J. Biol. Chem.265, 1268–1273 (1990).
R. Deana, M. Ruzzene, M. G. Doni, F. Zoccarato and A. Alexandre,Cyclic GMP and nitroprusside inhibit the activation of human platelets by fluoroaluminate. Biochim. Biophys. Acta1014, 203–206 (1989).
R. O. Morgan and A. C. Newby,Nitroprusside differentially inhibits ADP-stimulated calcium influx and mobilization in human platelets. Biochem. J.258, 447–454 (1989).
M.-F. Simon and H. Chap,Inhibition of calcium influx in thrombin-stimulated platelets by SIN-1, an activator of soluble guanylate cyclase. J. Cardiovasc. Pharmacol.14 (Suppl. 11), S106-S110 (1989).
R. E. Whatley, D. F. Fennell, J. A. Kurrus, G. A. Zimmerman, T. M. McIntyre and S. M. Prescott,Synthesis of plateletactivating factor by endothelial cells: the role of G proteins. J. Biol. Chem.265, 15550–15559 (1990).
D. H. Maurice and R. J. Haslam,Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: Inhibition of cyclic AMP breakdown by cyclic cGMP. Mol. Pharmacol.37, 671–681 (1990).
K. Schrör, H. Darius, R. Matzky and R. Ohlendorf,The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36374) — equipotent to PGI 2 in vitro. Naunyn-Schmiedeberg's Arch Pharmacol.316, 252–255 (1981).
A. B. Legrand, T. K. Narayanan, U. S. Ryan, R. S. Aronstam and J. D. Catravas,Modulation of adenylate cyclase activity in cultured bovine pulmonary arterial endothelial cells. Biochem. Pharmacol.38, 423–430 (1989).
G. Doni, R. Deana, S.D. Bertoncello, F. Zoccarato and A. Alexandre,Forskolin and prostacyclin inhibit fouoride induced platelet activation and protein kinase C dependent reponses. Biochem. Biophys. Res. Commun.156, 1316–1323 (1988).
E. R. Lazarowski and E. G. Lapetina,Activation of platelet phospholipase C is inhibited by elevation of cyclic AMP. Biochem. Biophys. Res. Commun.158, 440–444 (1989).
H. Schröder, H. Strohbach and K. Schrör,Nitric oxide but not prostacyclin is an autocrine endothelial mediator. Biochem. Pharmacol.43, 533–537 (1992).
H. Schröder and K. Schrör,Prostacyclin-dependent cyclic AMP formation in endothelial cells. NS Arch. Pharmacol.347, 101–104 (1973).
Y. Yada, S. Nagao, S. Okano and Y. Nozawa,Inhibition by cyclic AMP of guanine nucleotide-induced activation of phosphoinositide-specific phospholipase C in human platelets. FEBS Lett.242, 368–372 (1989).
J. G. de Mey, M. Claeys and P. M. Vanhoutte,Endothelium-dependent inhibitory effects of acetylcholine, adenosine diphosphate, thrombin and arachidonic acid in the canine femoral artery. J. Pharm. Exp. Ther.222, 166–173 (1982).
R. M. J. Palmer, A. G. Ferridge and S. Moncada,Nitric oxide release accounts for the biological activity of endotheliumderived relaxing factor. Nature327, 524–526 (1987).
W. Martin, D. G. White and A. H. Henderson,Endothelium-derived relaxing factor and atriopeptin II elevate cyclic GMP levels in pig aortic endothelial cells. Br. J. Pharmacol.93 229–239 (1988).
C. Boulanger, V. B. Schini, S. Moncada and P. M. Vanhoutte,Stimulation of cyclic GMP production in cultured endothelial cells of the pig by bradykinin, adenosine diphosphate, calcium ionophore A23187 and nitric oxide. Br. J. Pharmacol.101, 152–156 (1990).
G. M. Vercellotti, H. Q. Yin, K. S. Gustafson, R. D. Nelson and H. S. Jacob,Platelet-activating factor primes neutrophil responses to agonists: Role in promoting neutrophil-mediated endothelial damage. Blood71, 1100–1107 (1988).
P. Kubes, G. Ibbotson, J. Russell, J. L. Wallace and D. N. Granger,Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence. Am. J. Physiol.259, G300-G305 (1990).
F. A. Nicolini, P. Mehta, D. Lawson and J. L. Mehta,Reduction in human neutrophil chemotaxis by the prostacyclin analogue iloprost. Thromb. Res.59, 669–674 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Heller, R., Bussolino, F., Calvino, R. et al. S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells. Agents and Actions 40, 157–165 (1993). https://doi.org/10.1007/BF01984055
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01984055